Gamida Cell (NASDAQ:GMDA – Free Report) had its target price trimmed by HC Wainwright from $11.00 to $5.00 in a research note published on Wednesday morning, Benzinga reports. The brokerage currently has a buy rating on the stock. HC Wainwright also issued estimates for Gamida Cell’s Q4 2023 earnings at ($0.13) EPS, FY2023 earnings at ($0.66) EPS and FY2024 earnings at ($0.52) EPS.
GMDA has been the subject of several other reports. JMP Securities reaffirmed a market outperform rating and issued a $6.00 price objective on shares of Gamida Cell in a research note on Thursday, September 28th. Needham & Company LLC reaffirmed a buy rating and issued a $6.00 price objective on shares of Gamida Cell in a research note on Tuesday, August 15th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, Gamida Cell has a consensus rating of Buy and a consensus price target of $5.40.
Gamida Cell Price Performance
Institutional Inflows and Outflows
Several institutional investors have recently bought and sold shares of the company. Virtu Financial LLC bought a new stake in Gamida Cell during the 1st quarter valued at $26,000. Vanguard Personalized Indexing Management LLC bought a new stake in Gamida Cell during the 2nd quarter valued at $29,000. Lazard Asset Management LLC bought a new stake in Gamida Cell during the 2nd quarter valued at $30,000. Jane Street Group LLC bought a new stake in Gamida Cell during the 4th quarter valued at $33,000. Finally, Qube Research & Technologies Ltd bought a new stake in Gamida Cell during the 3rd quarter valued at $34,000. 42.74% of the stock is currently owned by hedge funds and other institutional investors.
Gamida Cell Company Profile
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with hematologic malignancies, as well as in Phase II clinical trials in patients with severe aplastic anemia.
- Five stocks we like better than Gamida Cell
- How to Calculate Return on Investment (ROI)
- S&P 500’s Whirlwind: Big gains, warning whispers & tactical moves
- What is Short Interest? How to Use It
- MarketBeat Week in Review – 11/13 – 11/17
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- 3 large caps with red hot RSIs with upside
Receive News & Ratings for Gamida Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gamida Cell and related companies with MarketBeat.com's FREE daily email newsletter.